| INTRODUCTION
Cardiovascular diseases are still the major cause of death worldwide. 1 The endothelium does not only form a physical barrier between blood and tissue but has important functional roles in regulation of trafficking, coagulation, and regulation of blood pressure. 2 Impaired endothelial function has been described in diverse disease conditions like diabetes, chronic kidney disease, and hypertension. [3] [4] [5] [6] Endothelial dysfunction precedes the full manifestation of many chronic diseases 7, 8 and may therefore be a very valuable diagnostic parameter useful for early treatment or prevention of cardiovascular diseases.
The common readout for endothelial function is the endothelium depending vasodilatation driven by the release of endothelium-derived relaxing factors (EDRFs), mainly nitric oxide (NO). The endothelium in its tissue surrounding is difficult to analyze but circulating endothelial cells (CECs) [9] [10] [11] may now offer a possibility to assess the integrity and function of the endothelium in order to confirm a diagnosis, predict the course of disease, or support treatment decisions. CECs have been microscopically described already decades ago 12 and their identity was confirmed by specific staining with endothelium-specific antibodies. 13, 14 The origin of CECs, their detection methods, and the association with cardiovascular diseases have been reviewed. 9, [15] [16] [17] [18] [19] Already during vascular damage, CECs are released into the bloodstream suggesting that their increase precede that of established tissue-damage markers like troponins or creatine kinase. Presently, CD146 is the most widely used surface marker for the detection of CECs, the specificity of the detection is sometimes enhanced by addition of other markers, eg, CD31, lack of CD45, or staining with UEA-1. 20 Mature CECs have to be discriminated from circulating endothelial progenitor cells (EPCs). The progenitor cells are responsible for repair and renewing of damaged endothelium because mature endothelial cells are believed to have only limited regenerative potential. 21 The progenitor cells are bone marrow-derived cells expressing CD34, CD133, and VEGFR2. Also vWF, CD117, and CD144
have been used as EPC markers but may be less specific. 22, 23 As with CECs, the exact definition and use of surface markers for EPCs is still under debate. 24 Although the protocols and surface markers used for enumeration of CECs and EPCs are quite diverse and also the reported baseline values for CECs in healthy volunteers vary significantly from 0 to 7900 cells per ml blood, 15 clear trends emerged from these studies:
Increased levels of CECs can be found in hypertension, diabetes, preeclampsia, and chronic kidney failure. In contrast, EPCs are reported to be reduced in subjects with cardiovascular risk factors and/or established atherosclerosis. [9] [10] [11] The clear association of CEC and EPC counts with cardiovascular disease biologically validates their potential to estimate the balance between endothelial damage and repair capacity, 9 but some efforts are still required to establish truly validated robust assays for the clinical use of these rare cell populations.
In this work, we established two multicolor flow cytometry panels to count and characterize CECs and EPCs in human whole blood. In order to ensure high quality data, the detection methods were validated based on sensitivity and reproducibility. As CECs counts are very low in healthy individuals the validation experiments for their detection were performed using whole blood samples from healthy donors spiked with human umbilical vein endothelial cells (HUVEC) and lung microvascular endothelial cells (L-HMVEC) at increasing concentrations. The experimental procedure was complemented with the use of transfix tubes in order to allow delayed analysis in multicenter studies. Finally, CECs and EPCs were quantified in patients with diabetic nephropathy (DN), heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), arterial hypertension (aHT), and age-matched healthy donors. Table S1 .
| MATERIAL AND METHODS

| Subjects and sample collection
Blood samples from patients and controls were drawn in Transfix/EDTA Blood collection tubes (Cytomark, UK). The first 3 mL of blood (potentially contaminated with endothelial cells from the venipuncture) were discarded. Samples were stored and shipped at 4°C and processed within 72 hours of blood collection. For assay validation experiments blood samples were also collected in tubes with Li-Heparin or EDTA for comparison.
| Flow cytometry
Circulating endothelial cells and EPCs were detected by flow cytometry using a panel of monoclonal antibodies and the nuclear staining Syto16
as listed in Tables S2 and S3 . CECs were defined as DNA + , CD45 dim ,
Essentials
• CEC and EPC levels are potential biomarkers of cardiovascular diseases.
• A robust and precise method for the quantification of CECs and EPCs was established.
• CECs and EPCs were quantified in HFpEF, HFrEF, DN, aHT, and healthy controls.
• CEC counts resulted to be a reliable diagnostic biomarker for DN and HFpEF. Figure S1 . An example of the flow cytometric gating strategy is depicted in Figure 1 . 
| Cell culture and cell spiking
The Cell were maintained in culture for no more than six culture passages.
For spiking experiments cells were harvested using Accutase (SigmaAldrich, St.Luis, MO, USA), and resuspended in phosphate-buffered saline without Ca 2+ Mg
2+
. After determining the cell concentration in a hemocytometer, the cell suspension was added to blood samples to achieve the theoretical cell concentrations of 100, 1000, and 10 000 
| Assay validation
To test the sensitivity of CEC quantification, blood samples from healthy donors were spiked with HUVECs or HMVECs at increasing concentrations in range 100-10 000 cells mL −1 as described in the previous section. The recovery rate of endothelial cells in spiked whole blood samples was calculated as: (detected ECs concentration)/(spiked EC concentration) × 100. Assay precision was determined using whole blood samples for EPC detection and whole blood samples spiked with HUVECs or HMVEC for CEC detection.
Intra-assay variability was determined by calculating cells counts in four aliquots of the same blood samples. Inter-assay variability and sample stability were determined by measuring the cell counts in duplicate in four independent assays on four different days (0 hour, 24 hours, 48 hours, and 72 hours after blood sampling). Coefficient of variation (CV) was calculated as standard deviation (SD)/average value × 100.
| Statistical analysis
Comparison between groups was performed using GraphPad soft- 
| RESULTS
| Detection of CECs and EPCs by flow cytometry
Circulating endothelial cells were detected by five-color flow cytometry using the nuclear staining Syto16 and monoclonal antibodies specific for the antigens CD45, CD31, CD146, and CD36. Figure 1B ). In particular, the gate for CD36 positivity was set comparing his fluorescence intensity on HUVECs, of macrovascular origin, and HMVECs, of microvascular cells. CEC analysis in patient samples confirmed the setting correctness, as showed in Figure 1A (CEC detected in a blood sample from a patient) and Figure 1B (CEC detected in a blood sample spiked with HMVEC). Antibody panel and gating strategy for EPCs were adapted from the method of Duda et al. 28 ( Figure 1C , and CD133 + EPCs were then identified. EPC identity was further confirmed analyzing CD31 expression. Positive/negative boundaries were set through FMO controls using matched isotype controls ( Figure S2 ).
| Detection recovery of CECs in whole blood samples
Assay sensitivity was assessed through spiking experiments, where known amounts of HUVECs and L-HMVECs (100, 1000, 10 000 cells 
| Sample stability and quantification assay precision
In preliminary experiments the quantification and stability of CEC and EPC levels was assessed in blood samples collected in EDTA, (Table 1) were lower than 20%, proving the reproducibility of the developed quantification method.
| CEC and EPC levels in clinical samples
Circulating endothelial cells and EPCs were quantified in patients with DN, HFpEF, HFrEF, aHT, and age matched healthy controls.
Patient characteristics are shown in Table S1 . 
| Diagnostic values of CEC count for DN and HFpEF
Comparing the cohorts of DN, HFpEF, HFrEF, and aHT with the healthy group we set the optimal CEC cutoff at 10.5 cells mL −1 (= median value + 1 SD in healthy controls), as shown in Figure 5C .
For the diagnosis of DN this cut-off gave a sensitivity of 68% (95% Figure 5A ,B. TA B L E 1 Assay precision. The intra assay variations were measured as the CV value of four replicates. The inter assay variations were calculated on three independent cell quantifications on the same blood samples Circulating endothelial cells have been described as a marker for damaged endothelium in several cardiovascular conditions such as chronic kidney disease, coronary heart disease, and peripheral arterial disease (described elsewhere 36 ).
| DISCUSSION
After optimizing the detection protocol, we tested CEC and EPC counts in patients with DN, HFpEF, HFrEF, or aHT, which may be caused or associated with endothelial dysfunction.
In patient samples from all tested indication, elevated CEC levels were detected, and these changes were highly significant in HFpEF and in DN. In patients with HFpEF and aHT there was also a significant increase in the proportion of microvascular CECs, as assessed by CD36 staining, in comparison to healthy individuals.
A similar finding was also reported in patient with Sickle cell anemia 31 and with pulmonary hypertension. 32 Elevated levels of CECs in heart failure have been described 37 with levels doubling in stable angina and approximately four-fold increase in acute heart failure but without discrimination between HFpEF and HFrEF. Our study is to our knowledge the first work that compared CEC counts between HFpEF and HFrEF.
Heart failure with preserved ejection fraction is an increasingly common condition which is difficult to diagnose. 38 This is an issue as some of the common treatments used for HFrEF, eg, β-blockers,
have not improved prognosis of HFpEV in clinical trials. 39 Better di- shown by Akiyama et al. 41 and has prognostic value. 42 Mohammed and colleagues also established that myocardial hypertrophy, increase calcium sensitivity and therefore prevent diastolic relaxation and lower PKG activity, which is required for Titin phosphorylation. Therefore, endothelial dysfunction is a mechanism contributing to HFpEF.
The CEC counts showed to be a highly specific marker for diagnosis of DN and HFpEF, but with limited sensitivity. There have been two previous studies that have investigated the diagnostic value of CECs in acute coronary syndrome (ACS). 16, 45 In both these investigations, CEC counts showed, in accordance with our results, high specificity but moderate sensitivity for ACS and for myocardial infarction (NSTEMI and STEMI).
With the improved sensitivity, our validated assay opens the perspective to a future use as additional diagnostic tool for early detection of cardiovascular diseases associated with endothelial damage.
In addition to CECs, EPCs were tested in our study. EPCs are usually quantified and analyzed by flow cytometry on fresh samples because of the high sensitivity and specific of this methodology. 46 In our study we quantified EPCs by flow cytometry adapting an antibody panel established by Duda et al. 28 EPC counts in healthy individuals were similar to those described by Duda et al. 28 Endothelial progenitor cell levels did not significantly change in patients in comparison to healthy individuals. We believe that the patients included in our study still were in relatively good condition as shown by their low NYHA status ( Table 1) , and that EPC counts are only reduced in the advanced disease stages.
Therefore, we conclude that the CEC level is a more sensitive marker for vascular damage compared to EPC level, which might be increased secondarily as a repair mechanism due to more severe vascular damage.
Future studies should concentrate on analyzing the diagnostic value of CEC counts in a broader range of cardiovascular diseases.
Determination of CEC counts during and after therapy will be crucial to understand their potential use for diagnosis and therapy monitoring. 47, 48 Elevated CEC counts may even serve as early diagnostic tool for endothelial damage in pre-symptomatic disease. As CECs are the more sensitive biomarker for endothelial damage, further efforts should concentrate on improving the sensitivity of CEC detection in order to increase diagnostic sensitivity.
The reliable isolation of CECs may also give rise to their functional characterization helping to increase the understanding of the underlying disease mechanisms. 
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